Usa experts Pregnancy patient Usa

Sage’s Zulresso for postpartum depression has uncertain payer coverage

Reading now: 634
www.pharmaceutical-technology.com

Analysts have been mostly positive on the uptake, and a report noted that Zulresso’s risk evaluation and mitigation strategies (REMS) requirement for continuous 60-hour assessment might complicate uptake, but it should be easily overcome as such monitoring is common practice.

However, experts said it will not be issues with REMS that impedes uptake, but the fact that many mothers might be unable to find support to care for their infants while admitted.

REMS is a drug safety programme that the US Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA